Roth Capital Has Positive Outlook of BRTX FY2024 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Roth Capital increased their FY2024 earnings per share (EPS) estimates for BioRestorative Therapies in a research note issued to investors on Thursday, November 14th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.43) per share for the year, up from their prior estimate of ($1.76). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at $3.43 EPS.

Separately, Roth Mkm raised their target price on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Price Performance

Shares of BioRestorative Therapies stock opened at $1.45 on Monday. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $3.67. The company’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.60. The stock has a market capitalization of $10.03 million, a PE ratio of -0.95 and a beta of 63.40.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.22. The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.30 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.